Well, thank you all for coming and those of you online for listening in.

And thank you especially to Marcodonia, for excellent work in immunotherapy and for the kind

invitation to come back to Denmark.

I'm happy to be interrupted at any time, if anyone has any questions, because

I know our backgrounds may be different. Not everyone here is a medical oncologist or a

hematologist oncologist, and so you have any questions about what I'm saying? Feel free to just

jump in. Put your hand up and I'll clarify, because probably somebody else will have the question

too. Okay, so we're going to talk about immunotherapy, promises, and limitations.

And by way of background, so I'm originally from outside of Chicago, Illinois, in America, and I did my medical school at University of Chicago.

I did internal medicine at Northwestern University, also in Chicago. I did my medical school at University of Chicago. I did internal medicine

at Northwestern University, also in Chicago. I did a program in hematology and oncology at the

National Cancer Institute. I was on the faculty in Portland, Oregon for five years before moving

to University of California, San Francisco. And I'm in clinic on Monday, Marcos on Thursday.

I'm in clinic Monday. And then the other days a week I teach some classes in epidemiology

and run a small research group.

We're always looking for people who are interested.

We have Zoom meetings with lots of European people.

So it's always in the morning for us and the afternoon for you.

Okay.

Let's get started.

I don't know, when you think about immunotherapy and you think about

checkpoint inhibitors like nivolomab, pembrylamimab, you think about carti therapy, like idia cells,

...